Informações de Novo Nordisk A/S

Mais detalhes de Novo Nordisk A/S Empresa

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.



Código da empresaNVO

Nome da EmpresaNovo Nordisk A/S

Data de listagemMay 17, 1974

CEOMr. Maziar Mike Doustdar

Número de funcionários76302

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 17

EndereçoNovo Alle 1

CidadeBAGSVAERD

Bolsa de valoresThe Toronto Stock Exchange

PaísDenmark

Código postal2880

Telefone4544448888

Sitehttps://www.novonordisk.com/

Código da empresaNVO

Data de listagemMay 17, 1974

CEOMr. Maziar Mike Doustdar

Executivos da empresa Novo Nordisk A/S



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - People, Organisation & Corporate Affairs

--

Dr. Martin Holst Lange

Executive Vice President, Chief Scientific Officer, Research & Development

--

Mr. Andreas Fibig

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Total GLP-1

5.83B

49.92%

Obesity (Wegovy®)

2.97B

25.41%

Fast-acting insulin

689.86M

5.91%

Long-acting insulin

678.47M

5.81%

Rare blood disorders

470.23M

4.03%

Outro

1.04B

8.92%

Por RegiãoUSD

Nome

Receita

Proporção

USA

6.53B

55.90%

Canada

2.50B

21.40%

Emerging Markets

1.15B

9.82%

APAC

852.83M

7.31%

Region China

651.28M

5.58%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Total GLP-1

5.83B

49.92%

Obesity (Wegovy®)

2.97B

25.41%

Fast-acting insulin

689.86M

5.91%

Long-acting insulin

678.47M

5.81%

Rare blood disorders

470.23M

4.03%

Outro

1.04B

8.92%

Distribuição de ações

Atualizado em: há 22 horas

Investidores

Tipos de investidores

Investidores

Proporção

Fidelity Management & Research Company LLC

0.38%

Loomis, Sayles & Company, L.P.

0.37%

Capital International Investors

0.35%

Fisher Investments

0.33%

Fayez Sarofim & Co.

0.31%

Outro

98.26%

Investidores

Proporção

Fidelity Management & Research Company LLC

0.38%

Loomis, Sayles & Company, L.P.

0.37%

Capital International Investors

0.35%

Fisher Investments

0.33%

Fayez Sarofim & Co.

0.31%

Outro

98.26%

Tipos de investidores

Investidores

Proporção

Investment Advisor

4.69%

Investment Advisor/Hedge Fund

2.73%

Research Firm

0.89%

Hedge Fund

0.40%

Pension Fund

0.32%

Insurance Company

0.19%

Bank and Trust

0.16%

Family Office

0.02%

Family Office

0.02%

Outro

90.58%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

2753

315.93M

9.39%

-25.52M

2025Q2

2754

330.35M

9.82%

-31.19M

2025Q1

2769

336.08M

9.99%

-21.71M

2024Q4

2676

348.53M

10.35%

+330.19K

2024Q3

2529

339.29M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.87M

2024Q1

2291

330.25M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.14M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Fidelity Management & Research Company LLC

12.93M

0.38%

+3.95M

+44.01%

Jun 30, 2025

Loomis, Sayles & Company, L.P.

12.58M

0.37%

+187.79K

+1.52%

Jun 30, 2025

Capital International Investors

11.62M

0.35%

+2.11M

+22.18%

Jun 30, 2025

Fisher Investments

11.00M

0.33%

-870.32K

-7.33%

Jun 30, 2025

Fayez Sarofim & Co.

10.50M

0.31%

-708.84K

-6.32%

Jun 30, 2025

Folketrygdfondet

10.09M

0.3%

+572.63K

+6.01%

Jun 30, 2025

Managed Account Advisors LLC

8.81M

0.26%

+195.59K

+2.27%

Jun 30, 2025

ClearBridge Investments, LLC

8.22M

0.24%

+1.59M

+23.95%

Jun 30, 2025

Everett Harris & Co.

6.39M

0.19%

-13.84K

-0.22%

Jun 30, 2025

Parametric Portfolio Associates LLC

6.23M

0.19%

+587.70K

+10.42%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: seg, 6 de out

Nome

Proporção

Roundhill GLP-1 & Weight Loss ETF

19.58%

Amplify Weight Loss Drug & Treatment ETF

9.11%

VanEck Pharmaceutical ETF

6.13%

The Opal International Dividend Income ETF

4.19%

TrueShares Low Volatility Equity Income ETF

2.57%

First Trust WCM International Equity ETF

2.28%

Invesco International Dividend Achievers ETF

1.16%

SP Funds S&P World (ex-US) ETF

1.13%

Amplify International Enhanced Dividend Income ETF

0.79%

ActivePassive International Equity ETF

0.79%

Ver Mais

Roundhill GLP-1 & Weight Loss ETF

Proporção19.58%

Amplify Weight Loss Drug & Treatment ETF

Proporção9.11%

VanEck Pharmaceutical ETF

Proporção6.13%

The Opal International Dividend Income ETF

Proporção4.19%

TrueShares Low Volatility Equity Income ETF

Proporção2.57%

First Trust WCM International Equity ETF

Proporção2.28%

Invesco International Dividend Achievers ETF

Proporção1.16%

SP Funds S&P World (ex-US) ETF

Proporção1.13%

Amplify International Enhanced Dividend Income ETF

Proporção0.79%

ActivePassive International Equity ETF

Proporção0.79%

Dividendo



Um total de 21.09B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Aug 06, 2024

NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Aug 26, 2024

Aug 16, 2024

Jan 31, 2024

NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024

Mar 25, 2024

Apr 02, 2024

Mar 22, 2024

Aug 10, 2023

NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023

Aug 21, 2023

Aug 29, 2023

Aug 18, 2023

Feb 02, 2023

NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023

Mar 27, 2023

Apr 04, 2023

Mar 24, 2023

Aug 04, 2022

NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022

Aug 15, 2022

Aug 23, 2022

Aug 12, 2022

Mar 02, 2022

NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022

Mar 28, 2022

Apr 05, 2022

Mar 25, 2022

Aug 05, 2021

NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021

Aug 17, 2021

Aug 25, 2021

Aug 16, 2021

Feb 22, 2021

NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021

Mar 29, 2021

Apr 07, 2021

Mar 26, 2021

Aug 06, 2020

NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020

Aug 17, 2020

Aug 25, 2020

Aug 14, 2020

Feb 06, 2020

NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020

Mar 30, 2020

Apr 07, 2020

Mar 27, 2020

Desdobramento de ações



Data

Tipo

Proporção

Aug 14, 2023

Split

1→2

Data

Tipo

Proporção

Aug 14, 2023

Split

1→2